(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
We may have one thing in common with jellyfish, new research finds - 2Instructions to Pick the Ideal SUV Size for Seniors
- 3Make your choice for a definitive Christmas place to get-away!
- 4Vote in favor of your #1 sort of juice
- 5Instructions to Construct an Organization While Chasing after a Web-based Degree
- 25 Years Ago, Audi's Rosemeyer Concept Was A Steampunk Supercar With A Massive Engine
- Michael Jordan donates $10M to North Carolina medical center in honor of his mother
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works.
- 19 Peculiar Films You Shouldn't Watch With Your Mum
- 5 Christmas movies to stream for less with this Paramount+ Black Friday deal
- Select Your Definitive Pizza Decision
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- Creative Do-It-Yourself Ventures for Each Expertise Level
